Related Experiment Video
Updated: Apr 1, 2026

The 6-hydroxydopamine Rat Model of Parkinson's Disease
Published on: October 27, 2021
Non motor subtypes and Parkinson's disease
Anna Sauerbier1, Peter Jenner2, Antoniya Todorova1
1National Parkinson Foundation International Centre of Excellence, King's College London, London, UK; National Institute for Health Research (NIHR), Mental Health Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and The Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.
Non-motor symptoms (NMS) are crucial in Parkinson's disease (PD), influencing diagnosis and potentially indicating distinct NMS subtypes. Research suggests these subtypes may be identifiable even in early, untreated PD patients.
Area of Science:
- Neurology
- Neuroscience
- Movement Disorders
Background:
- Non-motor symptoms (NMS) significantly impact Parkinson's disease (PD) progression.
- NMS are increasingly recognized as important in early and pre-motor stages of PD.
- The International Parkinson and Movement Disorder Society (IPMDS) is considering NMS in PD re-definition.
Purpose of the Study:
- To review NMS-dominant phenotypes in Parkinson's disease (PD).
- To explore pathophysiological concepts related to NMS subtypes.
- To propose potential NMS subtypes based on clinical data and biomarkers.
Main Methods:
- Literature review of clinical observational studies on NMS phenotypes in PD.
- Analysis of data-driven approaches identifying NMS clusters.
- Integration of clinical reports with potential biomarker evidence.
Main Results:
- Evidence suggests discrete non-motor subtypes exist in PD, especially in early and drug-naive patients.
- Independent studies have identified "clusters of NMS dominant PD".
- Specific NMS-dominant phenotypes have been described in both untreated and treated PD populations.
Conclusions:
- Non-motor symptoms define distinct phenotypes and potential subtypes of Parkinson's disease.
- Further research integrating clinical observations and biomarkers is needed to validate NMS subtypes.
- Recognizing NMS subtypes could refine PD diagnosis and management.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Neural Regulation
Lysosomal Hydrolases
Brainstem
The Midbrain
The midbrain is located beneath the diencephalon and connects the cerebrum with the lower parts of the brain. The cerebral peduncles are prominent midbrain structures that house the...

